Syniad’s Gemina Labs Announces Research Collaboration on Next-Generation Biosensors

December 19th 2022, Vancouver, British Columbia: Syniad Innovations Inc (“Syniad”) is pleased to announce that Gemina Laboratories Ltd.  (CSE: GLAB) (FRA: 817) (the “Company” or “Gemina”) has entered into a collaborative research partnership focused on the development of wearable biosensors with Dr. Amanda Clifford at the University of British Columbia.

Dr. Clifford is a researcher and Assistant Professor at the UBC Department of Materials Engineering. She holds a Bachelor of Engineering degree and a Ph.D. from the Department of Materials Science and Engineering at McMaster University. Dr. Clifford’s expertise and current research focus on the development of advanced materials for wearable healthcare monitoring and functional biointerfaces.

This collaboration will explore combining Gemina’s promising biorecognition technology with Dr. Clifford’s novel functional materials to enable portable, wearable, non-invasive, and continuous physiological monitoring. The goal of this initial research project is to conduct an initial proof of concept study to validate that the two technologies can be successfully integrated. It is a programme of work that lays the foundations for new types of diagnostic devices, including miniaturized, flexible electronic devices that can be worn in the mouth for continuous saliva-based testing and reporting.

“Gemina’s proprietary chemistry has consistently proven to be a highly effective and dynamic platform that allows for the development of best-in-class diagnostics for both medical and personal wellness point-of-care applications,” stated Gemina CTO Robert Greene. “Our vision for highly functionalized, next-generation biosensing is shared by Dr. Clifford. Her scientific acumen and current research program are a perfect match with our chemistry, and I am extremely excited to see what we can accomplish together over the next year.”

Brian Firth, Gemina CEO, commented, “The Gemina team is really pleased to be working with such an exciting scientist at the outset of her career. Dr. Clifford is doing inspiring work creating next-generation architectures of sensing applications for human health and wellbeing. This collaboration is a clear indication of the powerful potential of transformative chemistry, coupled with exciting new biosensing devices.”

Dr. Clifford added, “As a research scientist, my goal is to be able to translate new scientific breakthroughs into real world applications that help solve real problems. One of the great strengths of Gemina’s chemistry is that it can quickly and flexibly generate new prototype applications, which is a natural fit with my highly translational research program. I am really looking forward to seeing the first results of this work early in 2023.”

Learn more at: https://www.geminalabs.com/

Syniad Innovations is a company focused on building breakthrough deep tech companies around cutting-edge advances in science & engineering, like quantum networking.

Syniad addresses some of the world’s most pressing challenges by collaborating with exceptional researchers and provides the expertise, capital, and networks to help accelerate their ideas into important new products and services. Founded in 2015 in Vancouver, Syniad possesses a unique pedigree in research commercialization.

Our experience includes projects with various stakeholders, from Fortune 500 companies to governments and universities that want a step change in impact.